Ionis Pharmaceuticals reported strong Q3 2026 results but revealed that sales of its drug TRYNGOLZA for hypertriglyceridemia have been slower than expected. The company cut its full-year TRYNGOLZA sales forecast from $100-110 million to $50 million, though total revenue guidance remains unchanged. Following this announcement, Ionis' stock fell 21.4%, prompting a law firm to investigate potential claims from investors who suffered losses. This development highlights challenges in TRYNGOLZA's market performance and potential legal repercussions for the company.
Ionis Pharmaceuticals' stock is trading at USD 28.41 on Pluang as of Nov 10, 2026 23:13 WIB. The stock has declined 8.35% in the last day, showing continued market reaction to the company's revised sales forecast. Trading volume on Pluang reached 19,493,289 shares, with all orders currently on the buy side.
Ionis Pharmaceuticals' stock fell over 25% after its Q3 earnings report, despite beating revenue and EPS expectations and reaffirming 2026 guidance. The sharp decline was driven by a more than 50% cut in 2026 sales guidance for its drug Tryngolza, du...
Ionis Pharmaceuticals lowered its full-year 2026 sales guidance for its drug TRYNGOLZA from $100-$110 million to about $50 million, citing slower-than-expected market adoption. The drug had generated $32 million in sales in the first half of 2026 but...
Ionis Pharmaceuticals cut its 2026 sales forecast for TRYNGOLZA from $100-110 million to about $50 million due to a slower-than-expected commercial launch. This significant downgrade raised concerns about whether the company had previously disclosed ...
Ionis Pharmaceuticals sharply reduced its revenue guidance for one of its main drugs due to weak sales, causing its stock to fall significantly in premarket trading. This revenue cut overshadows the company's otherwise solid earnings report. The lowe...
